Tranzyme Pharma (TZYM -65.9%) says a Phase 3 trial of its treatment to speed up gastrointestinal...

|By:, SA News Editor

Tranzyme Pharma (TZYM -65.9%) says a Phase 3 trial of its treatment to speed up gastrointestinal recovery following abdominal surgery failed to meet its primary endpoint. TZYM, which had planned to test ulimorelin in several additional indications, says it will stop all other activities related to the filing of a new drug application.